Transient T cell therapies.
The pharmacological imperative for transient CAR expression is delineated, including lipid nanoparticles in combination with mRNA, which avoids risks of insertional mutagenesis and enables titratable, short-lived CAR expression, thereby enhancing safety management and suitability for applications beyond oncology.